Oppenheimer set a $95.00 target price on Neurocrine Biosciences (NASDAQ:NBIX) in a research note published on Monday morning. The firm currently has a buy rating on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ Q1 2018 earnings at ($0.16) EPS, Q2 2018 earnings at $0.02 EPS, Q3 2018 earnings at $0.26 EPS and FY2021 earnings at $7.36 EPS.
NBIX has been the topic of a number of other reports. Jefferies Group increased their price objective on Neurocrine Biosciences to $105.00 and gave the company a buy rating in a research report on Friday, January 5th. Citigroup reiterated a buy rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Needham & Company LLC reiterated a buy rating and issued a $86.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Piper Jaffray Companies reiterated a buy rating and issued a $76.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, October 25th. Finally, BMO Capital Markets reiterated an outperform rating and issued a $84.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 5th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $82.31.
Neurocrine Biosciences (NASDAQ NBIX) opened at $75.88 on Monday. The company has a market capitalization of $6,710.00, a price-to-earnings ratio of -34.18 and a beta of 0.35. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. Neurocrine Biosciences has a 12-month low of $38.43 and a 12-month high of $83.84.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the previous year, the business posted ($0.43) earnings per share. equities research analysts predict that Neurocrine Biosciences will post -1.61 earnings per share for the current fiscal year.
In related news, insider Darin Lippoldt sold 1,979 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $79.36, for a total transaction of $157,053.44. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kyle Gano sold 24,818 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total value of $1,763,318.90. Following the sale, the insider now directly owns 84,596 shares in the company, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. Insiders have sold a total of 116,405 shares of company stock worth $8,588,519 in the last ninety days. 4.80% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of NBIX. The Manufacturers Life Insurance Company raised its stake in shares of Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares during the period. Crow Point Partners LLC acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at about $145,000. Stephens Inc. AR acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $207,000. Comerica Bank acquired a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at about $210,000. Finally, Ardsley Advisory Partners acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $230,000.
WARNING: “Oppenheimer Analysts Give Neurocrine Biosciences (NBIX) a $95.00 Price Target” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/18/oppenheimer-analysts-give-neurocrine-biosciences-nbix-a-95-00-price-target.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.